Fortuin Suereta, Soares Nelson C
African Microbiome Institute, General Internal Medicine, Stellenbosch University, Cape Town, South Africa.
College of Pharmacy, University of Sharjah, Sharjah, United Arab Emirates.
Front Med (Lausanne). 2022 May 6;9:849838. doi: 10.3389/fmed.2022.849838. eCollection 2022.
Due to an increase in the overuse of antimicrobials and accelerated incidence of drug resistant pathogens, antimicrobial resistance has become a global health threat. In particular, bacterial antimicrobial resistance, in both hospital and community acquired transmission, have been found to be the leading cause of death due to infectious diseases. Understanding the mechanisms of bacterial drug resistance is of clinical significance irrespective of hospital or community acquired since it plays an important role in the treatment strategy and controlling infectious diseases. Here we highlight the advances in mass spectrometry-based proteomics impact in bacterial proteomics and metabolomics analysis- focus on bacterial drug resistance. Advances in omics technologies over the last few decades now allows multi-omics studies in order to obtain a comprehensive understanding of the biochemical alterations of pathogenic bacteria in the context of antibiotic exposure, identify novel biomarkers to develop new drug targets, develop time-effectively screen for drug susceptibility or resistance using proteomics and metabolomics.
由于抗菌药物的过度使用增加以及耐药病原体的发病率加速上升，抗菌药物耐药性已成为全球健康威胁。特别是，医院获得性和社区获得性传播中的细菌抗菌药物耐药性，已被发现是传染病死亡的主要原因。了解细菌耐药机制具有临床意义，无论其是医院获得性还是社区获得性，因为它在治疗策略和控制传染病中起着重要作用。在此，我们重点介绍基于质谱的蛋白质组学在细菌蛋白质组学和代谢组学分析中的进展——聚焦于细菌耐药性。过去几十年间组学技术的进步，如今使得进行多组学研究成为可能，以便全面了解病原菌在抗生素暴露情况下的生化改变，识别新型生物标志物以开发新的药物靶点，利用蛋白质组学和代谢组学高效地进行药物敏感性或耐药性的时效性筛选。
